First Capital Advisors Group LLC. Takes Position in Gilead Sciences, Inc. (GILD)

First Capital Advisors Group LLC. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 4,762 shares of the biopharmaceutical company’s stock, valued at approximately $337,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC raised its holdings in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. raised its holdings in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the period. American Beacon Advisors Inc. acquired a new stake in Gilead Sciences in the first quarter worth $143,000. Finally, Crestwood Advisors Group LLC raised its holdings in Gilead Sciences by 11.4% in the second quarter. Crestwood Advisors Group LLC now owns 2,730 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 279 shares during the period. Institutional investors own 73.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.truebluetribune.com/2017/10/13/first-capital-advisors-group-llc-takes-position-in-gilead-sciences-inc-gild.html.

Several research firms have weighed in on GILD. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective on the stock. in a report on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and set a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. Twelve analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $85.96.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 81.30 on Friday. The firm has a market capitalization of $106.17 billion, a PE ratio of 8.83 and a beta of 1.14. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company’s 50-day moving average is $82.03 and its 200-day moving average is $72.08.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the firm posted $3.08 earnings per share. Analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at $10,174,112. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The disclosure for this sale can be found here. Insiders have sold 486,819 shares of company stock worth $39,298,919 over the last three months. Insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply